...
【24h】

Reversible locoregional lymph node enlargement after radiofrequency ablation of lung tumors.

机译:射频消融肺肿瘤后可逆性局部淋巴结肿大。

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECTIVE: The objective of our study was to assess the characteristics of locoregional lymph node enlargement after successful radiofrequency ablation (RFA) in the treatment of malignant lung tumors. MATERIALS AND METHODS: Follow-up CT examinations of 14 patients (seven men, seven women; age range, 30-90 years) who underwent 16 RFA sessions for the treatment of primary (n = 9) or metastatic (n = 5) lung tumors with a mean follow-up of 35 +/- 15 (SD) months (range, 7-60 months) were retrospectively reviewed by two thoracic radiologists. The site and size of hilar and mediastinal lymph nodes were recorded at baseline and at follow-up 1, 3, and 6 months after RFA sessions. In addition, the size, type, and location of the ablated lesion or lesions were recorded. All complications from RFA were recorded. Data were analyzed using the Fisher's exact test. RESULTS: An increase in lymph node size was detected after 10 of 16 (62.5%) RFA sessions at 1-month follow-up. In four of 10 patients, only one node had enlarged, and in the remaining six patients, more than one nodal region had enlarged. The average increase in nodal size was 3 mm in the short-axis diameter and 4 mm in the long-axis diameter. Twenty-eight percent of RFA sessions were associated with enlargement of at least one lymph node to greater than 10 mm in short-axis diameter at 1-month follow-up. CT showed that nodes had decreased in size at 3- and 6-month follow-ups. Lesion size, location, and complications were not shown to be significantly associated with mediastinal lymph node enlargement (p > 0.05). CONCLUSION: Recognition of reversible locoregional lymph node enlargement after RFA is important to prevent misdiagnosis of nodal metastatic disease.
机译:目的:本研究旨在评估射频消融成功治疗恶性肺肿瘤后局部淋巴结肿大的特征。材料与方法:对14例行原发性(n = 9)或转移性(n = 5)肺部RFA治疗的患者(14例,男7例,女7例;年龄范围30-90岁)进行了CT随访检查。两名胸部放射科医生对平均随访时间为35 +/- 15(SD)个月(范围7-60个月)的肿瘤进行了回顾性检查。在RFA会议后的基线及随访1、3和6个月记录肺门和纵隔淋巴结的部位和大小。此外,记录消融灶或病变的大小,类型和位置。记录RFA的所有并发症。使用费舍尔精确检验分析数据。结果:在1个月的随访中,RFA疗程16次中有10次(62.5%)后,发现淋巴结大小增加。 10例患者中有4例只有一个淋巴结肿大,其余6例患者中有一个以上的淋巴结肿大。节点尺寸的平均增加在短轴直径上为3 mm,在长轴直径上为4 mm。在1个月的随访中,有28%的RFA会话与至少一个淋巴结增大至短轴直径大于10 mm有关。 CT显示,在3个月和6个月的随访中,淋巴结的大小有所减少。病变的大小,位置和并发症均未显示与纵隔淋巴结肿大显着相关(p> 0.05)。结论:RFA后可逆性局部淋巴结肿大的认识对预防淋巴结转移性疾病的误诊很重要。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号